Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.

ABSTRACT:

Background

With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research.

Setting

BRAAVE (NCT03631732) is a randomized, phase 3b, multicenter, open-label US study.

Methods

Adults identifying as Black or African American and virologically suppressed on 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus third agent were randomized (2:1) to switch to open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily or stay on baseline regimen (SBR) for 24 weeks, after which SBR had delayed switch to B/F/TAF. Resistance to non-NRTIs, protease inhibitors, and/or NRTIs was permitted; integrase strand transfer inhibitor resistance was exclusionary. Primary endpoint was proportion of participa

SUBMITTER: Hagins D 

PROVIDER: S-EPMC8357046 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature